2019 Summer Meeting – Manchester

14th July 2019 – 17th July 2019
Renold Building, University of Manchester

2019 Call for Symposium Proposals

A major topic at BAP Council meetings is planning the symposium programme for the summer meeting, which is the showcase event for the BAP. To ensure that the meeting is successful we need to provide a programme that is topical, well balanced and reflects the needs and interests of our Members. The best way that this can be achieved is to have substantial input from the membership.
We therefore encourage all BAP Members to think seriously about the topics that they would like to see in the summer meeting symposium programme, and to put forward proposals for consideration by Council. There are several factors that Council uses to assess proposals and which are important to consider when choosing the topic and content of symposia, including:

  • quality of the scientific information presented and the speakers (four in total)
  • topical nature of the subject
  • breadth of interest
  • relevance to, and inclusion of, clinical and nonclinical psychopharmacology
  • lack of overlap with, or repetition of, recent BAP symposia (see below)
  • geographical/institutional balance
  • the balance of symposium speakers/chairs which should reflect the BAP's statement on equality and diversity

BAP is able to provide the following for a maximum of four speakers/chairs:

  • Registration for the whole Summer Meeting
  • One nights’ accommodation
  • A ticket for the Gala Dinner
  • A contribution towards travel expenses:- £100 max for UK / £200 max for Europe / £500 max for RoW

Members who have ideas for the 2019 summer meeting (to be held at the Renold Building, University of Manchester from Sunday 14 to Wednesday 17 July), whether tentative or clearly formulated, are strongly encouraged to discuss these with a member of Council.

Proposals for symposia for the 2019 Summer Meeting should be submitted via the button below by no later than 9 March 2018, and will be discussed by the BAP Council at their March meeting.

Propose a Symposium

Previous Symposia


  • Early intervention for the next generation: Therapeutic challenges in youth mental health
  • Towards a mechanistic understanding of anxiety disorders: translational, pharmacological, neural and computational perspectives
  • PTSD; Exposure to traumatic events, brain changes and current and novel treatments
  • Microglia role in neuropsychiatric disease and its potential as a treatment target
  • New concepts in the co-morbidity of psychiatric disorders, eating disorders and obesity
  • Risk factors for autism and schizophrenia: Convergence or divergence?
  • The opiate system in addiction: latest findings from substance and behavioural addictions
  • Bridging the translational gap in psychiatry: a role for neuronal oscillations?
  • Mineralocorticoid/ glucocorticoid receptor imbalance and early life stress as risk factors for affective disorders


  • Personalized pharmacological treatments for depression: Will big data achieve what clinicians can't?
  • The psychopharmacology of emerging calcium channel targets
  • Behavioural and substance addictions: Similarities and differences
  • Adverse and beneficial effects of cannabinoids - new insights from genetics and clinical trials
  • The role of brain connectivity in brain disorders and their treatment
  • Psychopharmacology of the older and, almost certainly, degenerating brain
  • Treatment of dysfunction in hot and cold cognition in mood disorders
  • The brain-gut axis: Breaking the dichotomy between physical and mental health
  • Biomarkers of treatment response for schizophrenia and bipolar affective disorder: Latest updates


  • New paradigms and treatment approaches in schizophrenia
  • New perspectives on functions of 5-HT sub-systems
  • Towards a gender specific psychopharmacology: the impact of neurosteroids, gonadal steroids and oxytocin
  • Bipolar disorder: progress on many fronts
  • Ketamine and addiction: promising treatment or probable cause?
  • Neuronal stem cells in mental health: will neurogenesis and iPS cells give us the antidepressants of the future?
  • Anhedonia, apathy, amotivation, anergia? Disrupted reward processing as a trans-diagnostic construct in mental illness
  • Dysfunctional neuro-immune system interactions in psychiatric disorders and their relevance for novel treatment strategies
  • Innovation in the treatment of obesity and binge eating


  • Use and abuse of novel psychoactive substances
  • Bipolar disorder: looking to the future
  • Of models and men: translational imaging studies in advancing mechanistic understanding of neuropsychiatric diseases
  • Where now for glutamatergic strategies for schizophrenia?
  • Sleep and drugs in the 21st century
  • The Electronic cigarette: from basic pharmacology to smoking harm reduction and cessation
  • Advances in compulsivity: a trans-diagnostic perspective
  • The role of synaptic proteins in schizophrenia and related neurodevelopmental disorders
  • Non-invasive neurostimulation